Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification
Abiomed, Inc. (NASDAQ: ABMD) will announce its financial results for Q1 FY2022 on August 5, 2021. A conference call led by CEO Michael R. Minogue and CFO Todd Trapp will take place at 8:00 a.m. ET to discuss the outcomes. Investors can access the live call via a webcast or by phone. A replay will be available later on the same day. The company specializes in medical devices for circulatory support, aiding heart function and blood flow. For further details visit www.abiomed.com.
- Scheduled Q1 FY2022 earnings release on August 5, 2021.
- Conference call to discuss financial results enhances transparency.
- None.
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 5, 2021, the Company will release financial results for the first quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, August 5, 2021 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11:00 a.m. ET August 5, 2021 through 10:00 a.m. ET on August 12, 2021. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 5929017.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, including with respect to Abiomed's development of existing and new products, the Company's commercial growth, future business opportunities and pending regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements due to a number of factors, including uncertainties related to the scope, extent and duration of the impact of the COVID-19 pandemic, development, testing and related regulatory approvals, including the possibility of future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological changes, governmental requirements, litigation, future capital requirements and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent filings with the SEC. Readers of this press release are advised not to evaluate forward-looking statements, which reflect information available only as of the date of this release, as reliable information. The Company is under no obligation to release updates to these forward-looking statements to reflect events or circumstances occurring after the date of the release or as a result of the impact of unforeseen events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005238/en/
FAQ
What date will Abiomed release its Q1 FY2022 earnings?
Who will host the conference call for Abiomed's financial results?
How can I access the conference call for Abiomed's earnings?
What is the focus of Abiomed's business?
Will there be a replay available for Abiomed's earnings call?
